Apotex Achieves FDA Approval for Generic Infuvite® Injection with Exclusive Market Rights

Apotex Secures FDA Approval for Generic Infuvite® Adult Injection

Apotex Corp. made headlines recently with the announcement of FDA approval for its first generic version of Infuvite® Adult Injection. This approval, revealed on April 14, 2026, allows Apotex to market both the single-dose vial and pharmacy bulk package forms of this essential parenteral nutrition product. In collaboration with Orbicular Pharmaceutical Technologies and Gland Pharma, Apotex also garnered an exclusive 180-day Competitive Generic Therapy (CGT) designation for the pharmacy bulk package, establishing a significant market advantage for the company.

Christine Baeder, President of Apotex Corp. US LATAM, remarked, "Securing this approval reflects the strength of our partnership model and our shared commitment to supporting reliable access to high-quality injectable products for the U.S. market." This endorsement underscores the culmination of efforts by all partners involved in the development process.

The Significance of the Collaboration

This FDA approval represents a remarkable achievement in the collaboration between Apotex, Orbicular, and Gland Pharma. They worked together on a sophisticated sterile injectable program that not only incorporates scientific innovation but also regulatory strategy and commercial manufacturing readiness. Apotex takes the lead as the ANDA applicant, providing an overarching scientific strategy that guided the project while also spearheading U.S. commercialization efforts.

Orbicular Pharmaceutical Technologies played a vital role in the development of this product through comprehensive development activities. This included intricate emulsion-based formulation architecture and advanced analytical characterization, leading to the successful attainment of Drug Master File (DMF) approvals for thirteen multivitamins. Gland Pharma, meanwhile, showcased its robust manufacturing capabilities by preparing the sterile injectable infrastructure and executing validation batches that meet the stringent FDA requirements.

A Testament to Scientific Excellence

Dr. Hiren Patel, CEO of Orbicular, stated, "Achieving First ANDA approval with CGT designation for a complex formulation integrating 13 vitamins underscores our ability to convert high scientific complexity into commercially differentiated outcomes." Indeed, this milestone is a testament to nearly a decade of rigorous development efforts characterized by extensive iterations and adherence to evolving regulatory standards.

Srinivas Sadu, Executive Chairman of Gland Pharma, expressed the pride felt in achieving this significant milestone, emphasizing the company's strong capabilities in sterile injectables. He said, "This approval is the outcome of years of close collaboration, reflecting our ability to reliably support complex injectable programs for regulated markets."

About Apotex, Orbicular, and Gland Pharma

Apotex Corp., based in Weston, Florida, is a prominent player in the pharmaceutical sector, providing innovative medicines and health products to millions globally. Not only does Apotex focus on generic products, but it also emphasizes securing pharmaceutical licensing and product acquisitions across the Americas.

Orbicular Pharmaceutical Technologies, on the other hand, specializes in designing and delivering complex generics aimed at meeting high market demands through innovative collaborations. Founded in 1978, Gland Pharma has transformed into a leading injectable-focused company, operating across 60 countries and developing a wide range of sterile injectables.

The approval of the generic Infuvite® Adult Injection spotlights the dedication and cooperative spirit of these organizations, paving the way for improved patient access to medically necessary injectable products and reinforcing the commitment to delivering high-quality healthcare solutions.

In conclusion, this landmark approval marks a pivotal turning point not only for Apotex and its partners but also for the broader healthcare landscape in the United States. The combined efforts in scientific innovation, regulatory strategy, and manufacturing excellence are crucial for providing effective solutions in parenteral nutrition. Apotex's dedication to high-quality healthcare continues to shape the future of pharmaceuticals and patient care.